Sitamono Tablet 50 mg (Sitagliptin Hydrochloride Monohydrate)
Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Ildong Pharmaceutical Co., Ltd.
MFDS item code 202101849 · Approved 2021.02.24
This product's status changed to Approval withdrawn on 2025.08.12. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used in conjunction with dietary and exercise therapy to improve blood glucose control in patients with type 2 diabetes. It can be administered alone, and can be co-administered with metformin in cases where blood glucose control is inadequate with monotherapy and there has been no prior experience with diabetes medication. Additionally, it can be combined when blood glucose control is difficult using monotherapy with sulfonylureas, metformin, thiazolidinediones, or insulin. If the effect is insufficient even with combinations of various agents, this medication can be added to enhance blood glucose control.
Administer 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medication may be taken with or without food. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions). Patients with renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before treatment with this medication and periodically during treatment. 1. No dosage adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medication may be administered without regard to the timing of dialysis.
This medication may cause severe allergic reactions; therefore, if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur, discontinue use immediately and seek medical attention. While taking this medication, symptoms of acute pancreatitis, which is inflammation of the pancreas, may occur; if there is severe abdominal pain or vomiting, notify the healthcare provider immediately. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and also should not be administered to those with known allergies to this drug or its components. Patients with impaired renal function should have their dosage adjusted and regularly undergo renal function tests. Hypoglycemia may occur when this medication is used alone or in combination with other diabetes medications, so it is important to be well aware of hypoglycemia symptoms, especially when taken with insulin or sulfonylureas. During treatment with this medication, symptoms such as headache, upper respiratory tract infection, nasopharyngitis, diarrhea, nausea, etc. may occur; patients should consult a physician if the symptoms are severe or persistent. Women who are pregnant or breastfeeding are advised not to take this medication, and safety in children under 18 has not been established. Elderly patients should have dosage adjustments and renal function tests due to the potential for impaired renal function. In the case of overdose, seek medical attention immediately for appropriate treatment; this medication may be partially removed via hemodialysis. Furthermore, if patients experience severe joint pain or skin blisters during treatment with this medication, they must inform their doctor immediately; discontinuation and treatment may be necessary. Finally, this medication has relatively few drug interactions, but consultation with healthcare providers for appropriate monitoring is advised when taken concurrently with cyclosporine or digoxin.
Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, hypoglycemia, upper respiratory tract infection, nasopharyngitis, headache, diarrhea, abdominal pain, nausea, peripheral edema, constipation, vomiting, arthralgia accompanied by severe and disabling symptoms, vesicular pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute renal failure, pneumonia, diabetes complications, metabolic acidosis, falls, cardiac arrest, dyspepsia, dizziness, increased serum triglycerides, gastritis, elevated low-density lipoprotein, hyperglycemia, weight loss, hypertension, hypernatremia, erectile dysfunction
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container that does not allow air to penetrate, preferably between 1 degree to 30 degrees Celsius at room temperature. Proper storage will help maintain the drug's efficacy for a longer period.
A film-coated tablet that is round, biconvex, and light apricot in color
28 tablets/box [14 tablets/pity *2]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Ildong Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.